These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1968094)

  • 1. HIV-1 neutralizing antibodies in urine from seropositive individuals.
    Cao YZ; Friedman-Kien AE; Mirabile M; Li XL; Alam M; Dieterich D; Ho DD
    J Acquir Immune Defic Syndr (1988); 1990; 3(3):195-9. PubMed ID: 1968094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
    Swiderska H; Kalinowska B
    Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific western blot bands are associated with initial CD4+ lymphocyte counts in human immunodeficiency virus seroconverters. The Navy HIV Working Group.
    Garland FC; Garland CF; Gorham ED; Brodine SK; Weiss PJ
    Ann Epidemiol; 1994 Jan; 4(1):27-31. PubMed ID: 7911377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation of secretory antibodies in parotid saliva to human immunodeficiency virus type 1 with HIV-1 disease stage.
    Sun D; Archibald DW; Furth PA
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):933-41. PubMed ID: 2117957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
    Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers.
    Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP
    J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
    Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
    Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
    Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
    Höglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B
    Viral Immunol; 1990; 3(3):195-206. PubMed ID: 2257052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.
    Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG
    J Clin Microbiol; 1994 Jun; 32(6):1449-56. PubMed ID: 8077388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ELISA-inhibition assay for antibody to human immunodeficiency virus core antigen (p24).
    Povolotsky J; Gold JW; Darminin P; Chein N; Baron P; Armstrong D
    J Virol Methods; 1990 Oct; 30(1):109-14. PubMed ID: 2128300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.
    Cavacini LA; Emes CL; Power J; Underdahl J; Goldstein R; Mayer K; Posner MR
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1093-102. PubMed ID: 7692037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy.
    Böttiger B; Morfeldt-Månson L; Putkonen P; Nilsson B; Julander I; Biberfeld G
    Scand J Infect Dis; 1989; 21(5):507-14. PubMed ID: 2511625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
    Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.